LIVN LivaNova Plc

LivaNova to Present at the Stifel, Wolfe, and Piper Sandler Healthcare Conferences

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Vladimir Makatsaria, Chief Executive Officer, will present a general business update during fireside chats at the three following healthcare conferences in New York in November and December:

  • Stifel Healthcare Conference 2024 on Tuesday, November 19 from 11:30 a.m. - 12:00 p.m. Eastern Time,
  • 6th Annual Wolfe Research Healthcare Conference on Wednesday, November 20 from 1:20 - 1:50 p.m. Eastern Time, and
  • Piper Sandler Healthcare Conference on Tuesday, December 3 from 10:00 - 10:25 a.m. Eastern Time.

All three fireside chats will stream live with recordings available afterward. To access event links, visit the LivaNova website at .

About LivaNova

LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment to provide hope for patients and their families through medical technologies, delivering life-changing solutions in select neurological and cardiac conditions. Headquartered in London, LivaNova employs approximately 2,900 employees and has a presence in more than 100 countries for the benefit of patients, healthcare professionals and healthcare systems worldwide. For more information, please visit .

Safe Harbor Statement

This news release contains “forward-looking statements” concerning the Company’s goals, beliefs, expectations, strategies, objectives, plans, underlying assumptions, and other statements that are not necessarily based on historical facts. These statements include, but are not limited to, statements regarding participation in upcoming events. Actual events may differ materially from those indicated in our forward-looking statements as a result of various factors, including those factors set forth in Item 1A of the Company’s most recent Annual Report on Form 10-K, as supplemented by any risk factors contained in Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. LivaNova undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances.

EN
14/11/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on LivaNova Plc

 PRESS RELEASE

RECOVER Clinical Study Shows Meaningful Benefits of LivaNova’s VNS The...

LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that the journal Brain Stimulation has published two pivotal articles chronicling the unipolar cohort data set for the . The researchers evaluated the safety and efficacy of LivaNova’s VNS Therapy™ System and its effectiveness on quality of life and daily function in this population of patients with treatment-resistant unipolar depression. Overall, the articles concluded that active VNS Therapy, as compared with a no-stimulation control (or sham VNS Therapy), safely and effective...

 PRESS RELEASE

LivaNova to Present Scientific Data at American Epilepsy Society 2024 ...

LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced its participation in the American Epilepsy Society (AES) 2024 Annual Meeting, taking place December 6-10 in Los Angeles. The Company’s therapies and technologies for drug-resistant epilepsy treatment will be featured in numerous scientific posters to support a deeper understanding of the non-pharmacological treatment of seizures. LivaNova will also present in-progress data from its contemporary real-world evidence study, “CORE-VNS: Comprehensive Outcomes Registry in Subjects With...

 PRESS RELEASE

LivaNova to Present at the Stifel, Wolfe, and Piper Sandler Healthcare...

LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Vladimir Makatsaria, Chief Executive Officer, will present a general business update during fireside chats at the three following healthcare conferences in New York in November and December: Stifel Healthcare Conference 2024 on Tuesday, November 19 from 11:30 a.m. - 12:00 p.m. Eastern Time, 6th Annual Wolfe Research Healthcare Conference on Wednesday, November 20 from 1:20 - 1:50 p.m. Eastern Time, and Piper Sandler Healthcare Conference on Tuesday, December 3 from 10:00...

 PRESS RELEASE

LivaNova Announces OSPREY Clinical Study Meets Primary Safety and Effi...

LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that it met the primary endpoints for its . Together with its safety endpoints, the RCT achieved statistical significance of its primary endpoint responder rates1,2 between the treatment arm and the sham arm for the LivaNova aura6000™ System. The aura6000 is an implantable hypoglossal neurostimulator intended to treat adult patients with moderate to severe obstructive sleep apnea (OSA). In the OSPREY study, apnea-hypopnea index (AHI) and oxygen desaturation index (ODI) reductio...

 PRESS RELEASE

LivaNova Reports Third-Quarter 2024 Results

LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the quarter ended September 30, 2024 and raised full-year 2024 guidance. Financial Summary and Highlights(1) Third-quarter revenue of $318.1 million increased 11.2% on both a reported and constant-currency basis, as compared to the prior-year period. Excluding the impact of the Advanced Circulatory Support (ACS) segment wind down, revenue increased 12.3% on a constant-currency basis. Third-quarter U.S. GAAP diluted earnings per share of $0.60 and adjusted diluted...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch